Rani Therapeutics Holdings Inc
NASDAQ:RANI

Watchlist Manager
Rani Therapeutics Holdings Inc Logo
Rani Therapeutics Holdings Inc
NASDAQ:RANI
Watchlist
Price: 1.35 USD -0.74% Market Closed
Market Cap: 164m USD

Operating Margin

-3 727.8%
Current
Improving
by 505.6%
vs 3-y average of -4 233.4%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-3 727.8%
=
Operating Income
$-44.7m
/
Revenue
$1.2m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-3 727.8%
=
Operating Income
$-44.7m
/
Revenue
$1.2m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Rani Therapeutics Holdings Inc
NASDAQ:RANI
164m USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
524.6B USD
Loading...
CH
Roche Holding AG
SIX:ROG
274.5B CHF
Loading...
CH
Novartis AG
SIX:NOVN
219.4B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
206.8B GBP
Loading...
US
Merck & Co Inc
NYSE:MRK
276.4B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
147.2B USD
Loading...
No Stocks Found

Market Distribution

Lower than 95% of companies in the United States of America
Percentile
5th
Based on 14 112 companies
5th percentile
-3 727.8%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Rani Therapeutics Holdings Inc
Glance View

Market Cap
164m USD
Industry
Pharmaceuticals

Rani Therapeutics Holdings, Inc. operates as a clinical stage bio-therapeutics company providing technologies to enable the development of orally administered biologics. The company is headquartered in San Jose, California and currently employs 114 full-time employees. The company went IPO on 2021-07-30. The Company’s technologies enable the development of orally administered biologics. The firm has developed a drug-agnostic oral delivery platform, the RaniPill capsule, which delivers any drug, including molecules, such as peptides, proteins and antibodies. The RaniPill capsule delivers up to a three micrograms (mg) dose of the drug with high bioavailability. Its capsule includes a coating that is designed to withstand stomach acid but dissolves in the jejunum portion of the small intestine. The Company’s product candidate RaniPill capsule is in Phase I clinical trial. The Company’s RaniPill capsule is delivering a variety of biological therapeutics. Its pipeline includes core product candidate programs, such as RT-101, RT-105, RT-102, RT-109 and RT-110. The firm manufactures and assembles RaniPill capsules at its facilities in San Jose and Milpitas, California.

RANI Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-3 727.8%
=
Operating Income
$-44.7m
/
Revenue
$1.2m
What is Rani Therapeutics Holdings Inc's current Operating Margin?

The current Operating Margin for Rani Therapeutics Holdings Inc is -3 727.8%, which is above its 3-year median of -4 233.4%.

How has Operating Margin changed over time?

Over the last 9 months, Rani Therapeutics Holdings Inc’s Operating Margin has increased from -4 824.9% to -3 727.8%. During this period, it reached a low of -4 824.9% on Dec 31, 2024 and a high of -3 727.8% on Oct 30, 2025.

Back to Top